期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 130, 期 11, 页码 6109-6123出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI135528
关键词
-
资金
- French Public Bank of Investment (BPI EFFI-CLIN PSPC grant)
- French Institut National du Cancer [INCA MDSCAN PRT-K15-136]
- Regional Ligue Contre le Cancer 44
T cell exclusion causes resistance to cancer immunotherapies via immune checkpoint blockade (ICB). Myeloid cells contribute to resistance by expressing signal regulatory protein-alpha (SIRP alpha), an inhibitory membrane receptor that interacts with ubiquitous receptor CD47 to control macrophage phagocytosis in the tumor microenvironment. Although CD47/SIRP alpha-targeting drugs have been assessed in preclinical models, the therapeutic benefit of selectively blocking SIRP alpha, and not SIR gamma/CD47, in humans remains unknown, We report a potent synergy between selective SIRP alpha blockade and ICB in increasing memory T cell responses and reverting exclusion in syngeneic and orthotopic tumor models. Selective SIRP alpha blockade stimulated tumor nest T cell recruitment by restoring murine and human macrophage chemokine secretion and increased anti-tumor T cell responses by promoting tumor-antigen crosspresentation by dendritic cells. However, nonselective SIRP alpha/SIRP gamma blockade targeting CD47 impaired human T cell activation, proliferation, and endothelial transmigration. Selective SIRP alpha inhibition opens an attractive avenue to overcoming ICB resistance in patients with elevated myeloid cell infiltration in solid tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据